Tags

Type your tag names separated by a space and hit enter

Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants.
Pediatrics. 1987 Sep; 80(3):351-4.Ped

Abstract

Haemophilus influenzae vaccine containing polyribosyl ribitol phosphate (PRP) or PRP covalently linked to diphtheria toxoid (PRP-D) was given to 94 healthy infants 17 to 22 months of age at the same time, but not at the same site, as a diphtheria-tetanus-pertussis booster. Systemic reactions were similar in the two vaccine groups and resembled those expected with the diphtheria-tetanus-pertussis injection alone. Six (13%) and seven (14%) of the PRP and PRP-D recipients, respectively, had minor local reactions to the Haemophilus vaccine. Among the 77 children who were not already naturally immune (ie, anti-PRP antibody concentration of less than or equal to 0.15 micrograms of protein per milliliter) before vaccination, PRP-D was significantly more effective than PRP in inducing protective levels of antibody. Only 15 (43%) of the 35 nonimmune PRP recipients achieved a concentration of greater than or equal to 0.15 microgram/mL and only seven (20%) reached a concentration greater than or equal to 1.0 micrograms/mL following vaccination. In contrast, 34 (81%) of the 42 nonimmune recipients of PRP-D had a concentration of greater than or equal to 0.15 microgram/mL following vaccine and 32 (62%) had a concentration of greater than or equal to 1.0 micrograms/mL (P less than or equal to .001). These results suggest that more than one-half of nonimmune 18-month-old infants will not respond to PRP with protective levels of antibody. In light of the current data, recommendation for revaccination at 24 months of age for those immunized at any younger age is appropriate.

Authors

Hendley JO
No affiliation info available
Wenzel JG
No affiliation info available
Ashe KM
No affiliation info available
Samuelson JS
No affiliation info available

MeSH

Antibody FormationBacterial CapsulesBacterial VaccinesClinical Trials as TopicDiphtheria ToxoidDiphtheria-Tetanus-Pertussis VaccineDouble-Blind MethodDrug CombinationsHaemophilus InfectionsHaemophilus VaccinesHaemophilus influenzaeHumansImmunization ScheduleInfantPertussis VaccinePolysaccharidesPolysaccharides, BacterialRandom AllocationTetanus ToxoidVaccination

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

3306597

Citation

Hendley, J O., et al. "Immunogenicity of Haemophilus Influenzae Type B Capsular Polysaccharide Vaccines in 18-month-old Infants." Pediatrics, vol. 80, no. 3, 1987, pp. 351-4.
Hendley JO, Wenzel JG, Ashe KM, et al. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants. Pediatrics. 1987;80(3):351-4.
Hendley, J. O., Wenzel, J. G., Ashe, K. M., & Samuelson, J. S. (1987). Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants. Pediatrics, 80(3), 351-4.
Hendley JO, et al. Immunogenicity of Haemophilus Influenzae Type B Capsular Polysaccharide Vaccines in 18-month-old Infants. Pediatrics. 1987;80(3):351-4. PubMed PMID: 3306597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants. AU - Hendley,J O, AU - Wenzel,J G, AU - Ashe,K M, AU - Samuelson,J S, PY - 1987/9/1/pubmed PY - 1987/9/1/medline PY - 1987/9/1/entrez SP - 351 EP - 4 JF - Pediatrics JO - Pediatrics VL - 80 IS - 3 N2 - Haemophilus influenzae vaccine containing polyribosyl ribitol phosphate (PRP) or PRP covalently linked to diphtheria toxoid (PRP-D) was given to 94 healthy infants 17 to 22 months of age at the same time, but not at the same site, as a diphtheria-tetanus-pertussis booster. Systemic reactions were similar in the two vaccine groups and resembled those expected with the diphtheria-tetanus-pertussis injection alone. Six (13%) and seven (14%) of the PRP and PRP-D recipients, respectively, had minor local reactions to the Haemophilus vaccine. Among the 77 children who were not already naturally immune (ie, anti-PRP antibody concentration of less than or equal to 0.15 micrograms of protein per milliliter) before vaccination, PRP-D was significantly more effective than PRP in inducing protective levels of antibody. Only 15 (43%) of the 35 nonimmune PRP recipients achieved a concentration of greater than or equal to 0.15 microgram/mL and only seven (20%) reached a concentration greater than or equal to 1.0 micrograms/mL following vaccination. In contrast, 34 (81%) of the 42 nonimmune recipients of PRP-D had a concentration of greater than or equal to 0.15 microgram/mL following vaccine and 32 (62%) had a concentration of greater than or equal to 1.0 micrograms/mL (P less than or equal to .001). These results suggest that more than one-half of nonimmune 18-month-old infants will not respond to PRP with protective levels of antibody. In light of the current data, recommendation for revaccination at 24 months of age for those immunized at any younger age is appropriate. SN - 0031-4005 UR - https://www.unboundmedicine.com/medline/citation/3306597/Immunogenicity_of_Haemophilus_influenzae_type_b_capsular_polysaccharide_vaccines_in_18_month_old_infants_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓1]

Related Citations

More